RED:1,2 NICE TA238: Arthritis (juvenile idiopathic, systemic) recommended if NSAIDs, steroids and methotrexate have failed (decision date - January 2012)
RED:1,2 NICE TA247: Rheumatoid arthritis: Tocilizumab (with methotrexate) – a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated (decision date - March 2012)
RED:1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (This TA partially replaces TA247) (Decision date - February 2016)
RED:1,2,3 NICE TA373 for treating juvenile idiopathic arthritis (JIA). (Decision date - January 2016)
RED:1,2,3 NICE TA518: for the treatment of giant cell arteritis. (Decision date - May 2018)
RED: NICE TA878: people admitted to hospital with COVID-19 who need high-flow oxygen: tocilizumab can be offered, subject to eligibility criteria, through the UK interim clinical commissioning policies for secondary care. (Decision date - April 2023)
NHS England is the responsible commissioner for JIA and giant cell arteritis.